DUBLIN, Oct. 24, 2024 (Globe Newswire) — The “Small Molecule Drug Discovery – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
The global market for small molecule drug discovery was estimated at USD 40.2 billion in 2023 and is projected to reach USD 58.4 billion by 2030, growing at a CAGR of 5.5% from 2023 to 2030. This comprehensive report provides a detailed analysis of the market. Understand trends, drivers, and forecasts to help you make informed business decisions.
The growth of the small molecule drug discovery market is driven by several factors, including increasing focus on targeted therapies and personalized medicine, advances in high-throughput screening, AI-based drug discovery techniques, and computational drug discovery techniques. Increased collaboration between pharmaceutical companies, research institutions, and CROs is driving market adoption of oncology, neurology, and immunology research.
The growing demand for oral small molecule therapeutics with improved bioavailability, safety, and efficacy profiles is expanding the market scope among diverse therapeutic areas. Proliferation of pipeline molecules, expiration of key biological patents, and development of small molecule drug conjugates (SMDCs) are creating new opportunities for market growth. Additionally, increasing investments in research and development of innovative drug discovery platforms, adoption of fast track and orphan drug designations, and growing outsourcing of drug discovery activities are further supporting market expansion.
Why is small molecule drug discovery important to modern medicine?
Small molecule drug discovery is at the core of modern medicine and focuses on developing therapeutics that can modulate specific biological pathways and targets to treat a wide range of diseases. Small molecules, typically low molecular weight compounds, have the advantage of being easily absorbed, distributed, metabolized, and excreted in the human body, making them ideal candidates for oral administration.
These drugs play an important role in the treatment of complex conditions such as cancer, cardiovascular disease, neurological disorders, and infectious diseases. The demand for small molecule drug discovery is increasing, with increasing emphasis on targeted therapy, personalized medicine, and the development of novel small molecule drugs for rare diseases and unmet medical needs.
How are technological advances changing small molecule drug discovery?
Technological advances are transforming small molecule drug discovery by increasing the efficiency, speed, and precision of the drug discovery process. The integration of high-throughput screening (HTS), computational drug design, and AI-driven predictive modeling enables researchers to identify potential drug candidates with high accuracy. The use of big data analytics and machine learning algorithms is revolutionizing the discovery process by analyzing large datasets and predicting drug-target interactions, toxicity, and efficacy.
The advent of fragment-based drug discovery (FBDD) and structure-based drug discovery (SBDD) approaches has enabled the identification of high-affinity compounds that can be optimized into potent therapeutics. These innovations are reducing the time, cost, and risk of drug development and increasing collaboration between pharmaceutical companies, research institutions, and contract research organizations (CROs).
Which market segments are driving the adoption of small molecule drug discovery?
Therapeutic areas include oncology, neurology, immunology, cardiovascular diseases, infectious diseases, and metabolic diseases, with oncology accounting for the largest market share due to the high prevalence of cancer and the demand for targeted therapies. occupied. Technologies include high-throughput screening, computational drug design, bioinformatics, and combinatorial chemistry, with high-throughput screening leading the market due to its efficiency in screening large compound libraries.
End users include pharmaceutical companies, biotech companies, academic research institutions, and CROs. Pharmaceutical companies are the primary adopters because of their focus on developing first-in-class and best-in-class treatments. Geographically, North America and Europe are the largest markets for small molecule drug discovery due to advanced medical infrastructure and significant R&D investment, while Asia Pacific is experiencing rising healthcare spending and the biopharmaceutical industry. Due to expansion, it is emerging as a high-growth region.
Key insights:
Market Growth: Understand the significant growth trajectory of the oncology drug segment expected to reach USD 24.9 billion by 2030 at a CAGR of 6.7%. The central nervous system therapeutics segment is also expected to grow at a CAGR of 5.9% during the analysis period. Regional analysis: Gain insight into the US market, estimated at $11 billion in 2023, and the Chinese market, expected to grow by an impressive $510 million. The CAGR % is expected to reach $9.1 billion by 2030. Check out growth trends in other key regions such as Japan, Canada, Germany, and Asia Pacific.
Report features:
Comprehensive market data: Independent analysis of annual sales and market forecasts (USD million) from 2023 to 2030. Detailed regional analysis: Detailed insights into key markets including the US, China, Japan, Canada, Europe, Asia Pacific, and Latin. America, Middle East, Africa. Company Overview: Covers major companies such as AstraZeneca PLC, Boehringer Ingelheim International GmbH, and Bristol-Myers Squibb Company. Free updates: Receive 1 year of free report updates to stay informed. Latest market trends.
Key attributes:
Report attribute details No. Number of pages 184 Forecast period 2023 – 2030 Estimated market value in 2023 (USD) 40.2 billion USD Predicted market value by 2030 (USD) 58.4 billion USD Average annual growth rate 5.5% Target region Worldwide
Main topics covered:
Market overview
Influencer Market Insights Global Market Trajectory Global Economic Updates Small Molecule Drug Discovery – Market Share Percentages of Major Competitors Worldwide in 2024 (E) Competitive Market Presence – Global Market Shares in 2024 Powerful/Active/Niche/Mediocre for Players (E)
Market trends and drivers
Increasing focus on targeted therapies and personalized medicine drives small molecule drug discovery market Advances in high-throughput screening (HTS) and computational drug design drive market innovation Growth in oncology, neurology, and immunology research , addressable small molecule drug market expands Focus on first-in drug development Best-in-class small molecule therapeutics drive market demand Integration of AI, machine learning, and big data analytics in drug discovery accelerates market transformation Emergence of small molecule drug conjugates (SMDCs) expands market reach Expanding use of fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) drive adoption of oral drugs with better bioavailability Increasing demand for small molecule therapeutics strengthens market position Focus on enhancing target selectivity, efficacy, and safety profile sustains market growth with proliferation of pipeline molecules and key biological Patent expiration fuels growth in small market for molecular drug discovery
Focus on carefully selected players (21 players in total)
AstraZeneca PLCBoehringer Ingelheim International GmbHBristol-Myers Squibb CompanyGilead Sciences, Inc.GlaxoSmithKline PLCJohnson & JohnsonMerck & Co., Inc.Pfizer, Inc.Teva Pharmaceutical Industries Ltd.
For more information about this report, please visit https://www.researchandmarkets.com/r/q6i8qa.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.
Small molecule drug discovery market
